The company sees increased traction in its core segment of studies of evaluating the generic versions of proprietary drugs that go off patent, as well bright prospects from clinical trials of biosimilars and novel drugs.Veeda Clinical Research filing for Rs 500 crore - Rs 700 crore IPO, sources say
The company sees increased traction in its core segment of studies of evaluating the generic versions of proprietary drugs that go off patent, as well bright prospects from clinical trials of biosimilars and novel drugs.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment